Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery

Last updated: January 26, 2015
Sponsor: Asklepion Pharmaceuticals, LLC
Overall Status: Completed

Phase

3

Condition

Holoprosencephaly

Birth Defects

Treatment

N/A

Clinical Study ID

NCT00335244
409
IRB# 060197
R01HL073317-01
  • Ages < 17
  • All Genders

Study Summary

This clinical trial will determine the safety and effectiveness of intravenous L-citrulline in children undergoing cardiopulmonary bypass during heart surgery. Participants will be randomly assigned to either L-citrulline or a placebo (a substance that has no medicine in it).

Citrulline is a protein building block in the body that can convert into another substance, nitric oxide (NO), which controls blood pressure in the lungs. Increased blood pressure in the lungs can be an important surgical problem; it may also lead to problems following surgery, such as severe high blood pressure in the lungs (pulmonary hypertension), increased time spent on a breathing machine, and a longer stay in the intensive care unit (ICU). The hypothesis of this study is that perioperative supplementation with intravenous citrulline will increase plasma citrulline, arginine and NO metabolites and prevent elevations in the postoperative PVT leading to a decrease in the duration of postoperative invasive mechanical ventilation.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Undergoing cardiopulmonary bypass surgery with 1 of the following 5 procedures:

  1. AVSD repair

  2. VSD repair

  3. Bidirectional Glenn

  4. Modified Fontan

  5. Arterial switch

Exclusion

Exclusion Criteria:

  • Pulmonary artery or vein abnormalities not being addressed surgically

  • Preoperative requirement for mechanical ventilation or intravenous inotrope support

  • Any condition that might interfere with study objectives, as determined by theinvestigator

  • Pregnant

Study Design

Total Participants: 77
Study Start date:
May 01, 2006
Estimated Completion Date:
December 31, 2009

Study Description

Increased pulmonary vascular tone (PVT) can complicate the postoperative course of the following five surgical procedures for congenital heart defects: 1) unrestrictive ventricular septal defect (VSD) repair; 2) atrioventricular septal (AVSD) repair; 3) arterial switch procedure for transposition of the great arteries (TGA); 4) bidirectional Glenn shunt procedure; and 5) Fontan procedure for single ventricle lesions. PVT is partially controlled by NO. Arginine, the precursor to NO, is a product of the urea cycle. Preliminary data have been presented regarding 169 infants and children who have undergone one of six previous surgical procedures. It was found that urea cycle function and plasma arginine levels were significantly decreased in all participants. Furthermore, participants with increased PVT had significantly lower arginine levels compared to participants with normal PVT. Finally, a genetic single nucleotide polymorphism (SNP) in the rate limiting urea cycle enzyme (carbamyl phosphate synthetase I [CPSl T1405N]) appeared to affect postoperative plasma arginine levels and PVT. The hypothesis is that genetic polymorphisms in the rate limiting urea cycle enzyme CPSl, and other important enzymes in the urea cycle, influence the availability of NO precursors. It is further hypothesized that perioperative enhancement of urea cycle function with the key urea cycle intermediate (citrulline) will increase plasma arginine and NO metabolites and prevent elevations in PVT.

Connect with a study center

  • Vanderbilt University Medical Center

    Nashville, Tennessee 37232
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.